Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA).

Schizophrenia Bulletin 47 (2), pp. 505-516. 10.1093/schbul/sbaa128

Publishers page: http://dx.doi.org/10.1093/schbul/sbaa128
<http://dx.doi.org/10.1093/schbul/sbaa128>

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA)

Alice Egerton1,2, Anna Murphy3, Jacek Donocik1, Adriana Anton4, Gareth J. Barker2,5, Tracy Collier1,2, Bill Deakin3, Richard Drake1,6, Emma Eliasson7, Richard Emsley1,2, Catherine J. Gregory3, Kira Griffiths1, Shitij Kapur1,2,9, Laura Kassoumeri1,2, Laura Knight10, Emily J. B. Lambe10, Stephen M. Lawrie7, Jane Lees7, Shôn Lewis4, David J. Lythgoe1,8, Julian Matthews3, Philip McGuire1,2, Lily McNamee5,8, Scott Semple11, Alexander D. Shaw10, Krish D. Singh10, Charlotte Stockton-Powdrell7, Peter S. Talbot3, Mattia Veronese2,2, Ernest Wagner7, James T. R. Walters12, Stephen R. Williams13, James H. MacCabe1,15, and Oliver D. Howes1,14,15

1Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London SE5 8AF, UK; 2NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, London, UK; 3Division of Neuroimaging, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK; 4Academic Unit of Radiology, Medical School, Faculty of Medicine, Dentistry & Health, University of Sheffield, Sheffield S10 2JF, UK; 5Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London SE5 8AF, UK; 6Division of Psychology and Mental Health, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK; 7Division of Psychiatry, University of Edinburgh, Edinburgh, UK; 8Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London SE5 8AF, UK; 9Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia; 10CUBRIC, School of Psychology, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF24 4HQ, UK; 11Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH1 6JF, UK; 12MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff CF24 4HQ, UK; 13Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, UK; 14Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London W12 0NN, UK; 15J.H.M. and O.D.H. share senior authorship.

*To whom correspondence should be addressed; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, 16 De Crespigny Park, London, SE5 8AF, UK; tel: (+44)-207-848-0721, fax: +44 207 848 0976, e-mail: Alice.Egerton@kcl.ac.uk

The variability in the response to antipsychotic medication in schizophrenia may reflect between-patient differences in neurobiology. Recent cross-sectional neuroimaging studies suggest that a poorer therapeutic response is associated with relatively normal striatal dopamine synthesis capacity but elevated anterior cingulate cortex (ACC) glutamate levels. We sought to test whether these measures can differentiate patients with psychosis who are antipsychotic responsive from those who are antipsychotic nonresponsive in a multicenter cross-sectional study. 1H-magnetic resonance spectroscopy (1H-MRS) was used to measure glutamate levels (Glucorr) in the ACC and in the right striatum in 92 patients across 4 sites (48 responders [R] and 44 nonresponders [NR]). In 54 patients at 2 sites (25 R and 29 NR), we additionally acquired 3,4-dihydroxy-6-18F]fluorophenylalanine ([F-DOPA] positron emission tomography (PET) to index striatal dopamine function (Kcorr, min⁻¹). The mean ACC Glucorr was higher in the NR than the R group after adjustment for age and sex (Pcorr = 4.27; P = .04). This was associated with an area under the curve for the group discrimination of 0.59. There were no group differences in striatal dopamine function or striatal Glucorr. The results provide partial further support for a role of ACC glutamate, but not striatal dopamine synthesis, in determining the nature of the response to antipsychotic medication. The low discriminative accuracy might be improved in groups with greater clinical separation or increased in future studies that focus on the antipsychotic response at an earlier stage of the disorder and integrate other candidate predictive biomarkers. Greater harmonization of multicenter PET and 1H-MRS may also improve sensitivity.

Key words: 1H-MRS/PET/antipsychotic response, treatment resistance/schizophrenia

© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

The degree to which symptoms of schizophrenia will improve with antipsychotic medication is extremely variable. For some patients, antipsychotics can be very effective in improving symptoms. However, a majority of patients experience only a partial improvement, and around a third of all patients meet criteria for treatment-resistant schizophrenia (TRS), for which the only recommended antipsychotic is clozapine. The difficulty of identifying TRS by clinical criteria, combined with a reluctance to prescribe clozapine, leads to a delay in clozapine initiation during which time patients are exposed to ineffective medications and symptoms are active and disabling. There is an initial indication that delay in clozapine prescription is associated with a worse response when clozapine is eventually prescribed.

Emerging biological and epidemiological evidence suggests that antipsychotic nonresponsive illness could be categorically distinct from antipsychotic responsive illness. Elucidating the pathophysiology of antipsychotic nonresponse could identify new targets for drug development and could also enable the development of predictive biomarkers to identify such patients early in the illness, allowing treatment with clozapine to begin earlier.

A prominent neurochemical hypothesis of schizophrenia centers on elevated dopamine synthesis and release in the striatum, arising from increased activity in mesostriatal dopamine neurons. The blockade of striatal D2 dopamine receptors is considered a critical feature of antipsychotic efficacy. While the response may require a threshold level of D2 occupancy, in antipsychotic nonresponsive schizophrenia, symptoms may persist despite high levels of D2 blockade. This raises the possibility that antipsychotic nonresponsive patients have a different pathophysiology that is not addressed by D2 blockade. Recently, molecular imaging studies have shown that striatal dopamine synthesis capacity is lower in TRS relative to that in patients who respond to antipsychotics. In longitudinal studies, higher levels of striatal D2 occupancy by dopamine and striatal dopamine synthesis capacity are associated with a greater response to antipsychotic treatment. Thus, biomarkers of striatal hyperdopaminergia may be predictive of an increased likelihood to respond to first-line (D2 blocking) antipsychotic treatment.

If TRS is not associated with abnormal striatal dopamine synthesis capacity, then the pathophysiology probably lies elsewhere. One possibility is that TRS arises due to abnormal glutamatergic signaling, particularly in cortical areas. A series of cross-sectional studies have indicated that poor antipsychotic response is associated with a higher level of glutamate metabolites in the anterior cingulate cortex (ACC) relative to levels in patients who have shown a good response or healthy volunteers. In first-episode psychosis, a higher level of ACC glutamate is predictive of a worse response to antipsychotic treatment. Higher frontal glutamate metabolites are also predictive of a poor response following reintroduction of antipsychotic treatment. In the striatum, glutamate metabolites may be elevated at illness onset but the relationship with the antipsychotic response is less clear. These observations may be particularly important in the context of the substantial efforts to develop glutamatergic drugs for schizophrenia, as they may suggest that glutamate modulation may be more effective in TRS than in antipsychotic-responsive patients.

So far, cross-sectional studies of dopaminergic or glutamatergic function in relation to antipsychotic response have been single-center studies that have recruited relatively small and homogenous patient cohorts. A key step in scaling this research toward developing predictive biomarkers for future stratified clinical trials is to test for these associations in a larger, more clinically representative patient sample and to determine the accuracy of group discrimination. The main aim of the current study was, therefore, to determine if glutamate levels in the ACC and striatum and striatal dopamine synthesis capacity differentiate antipsychotic nonresponsive illness from antipsychotic responsive psychosis in a multicenter cross-sectional sample. We hypothesized that, compared with the antipsychotic-responsive psychotic group, antipsychotic nonresponse would be characterized by lower striatal dopamine synthesis capacity and higher glutamate levels in the striatum and ACC. A secondary aim was to investigate relationships between ACC and striatal glutamate and striatal dopamine synthesis capacity in the same individuals.

Methods

Regulatory Approvals

The study had NHS Research Ethics Committee (15/LO/0038) and Administration of Radioactive Substances Advisory Committee (630/3764/32558) approvals. Participation required the provision of written informed consent.

Participants

Study participants were recruited and assessed across 4 UK sites: King’s College London (KCL), University of Manchester (UoM), University of Edinburgh (UoE), and Cardiff University (CU). Inclusion criteria required that participants were aged between 18 and 65, met Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for schizophrenia or schizoaffective disorder, and were able to understand and consent to the study procedures. Exclusion criteria included currently meeting International Classification of Diseases (ICD) criteria for harmful substance misuse, or psychotic disorder secondary to substance misuse, pregnancy, previous severe head injury involving loss of consciousness for >5 minutes, and for Magnetic Resonance Imaging (MRI)
presence of any contraindications to MRI at 3 tesla including implanted electronic devices or metallic objects. Treatment with clozapine in the last 3 months was an exclusion criterion, as the superior efficacy of clozapine in TRS could reflect differential biological effects. The cohort reflect a new patient sample, separate to those in our previous reports. Volunteers were reimbursed for participating in MRI and positron emission tomography (PET) scans.

The Mini International Neuropsychiatric Interview (MINI) was used to aid clinical diagnosis. Medication history and antipsychotic response were recorded through a structured interview and review of medical records. Antipsychotic doses were converted to chlorpromazine equivalent (CPZE) doses using the method of Davis and Chen, with the exception of amisulpride that used defined daily dose (https://www.whocc.no/ddd-index/). Illness severity was evaluated using the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression scale for Schizophrenia (CGI-SCH).

Definition of Antipsychotic Responder and Antipsychotic Nonresponder groups

Antipsychotic Responders (R) were defined as having had (1) treatment with only 1 antipsychotic drug since illness onset, or, if there were any treatment changes, then these were due to adverse effects as opposed to nonresponse; (2) a CGI-SCH severity score of <4; (3) a PANSS total score of <60; and (4) a compliance rating scale (CRS) score of >3.

Antipsychotic nonresponders (NR) were defined as having (1) documented treatment with at least 2 antipsychotics for >4 weeks each, at doses above the minimum therapeutic doses as defined by the British National Formulary; (2) a CGI-SCH severity score of >3; (3) a PANSS total score of at least 70; and (4) a CRS of >3. The targets for participant enrollment differed by site, but each site aimed to recruit a 1:1 ratio of R and NR.

Proton Magnetic Resonance Spectroscopy

Glutamate levels were measured using 1H-MRS. Non-rotated 1H-MRS voxels were positioned in the ACC (20 × 20 × 20 mm3; supplementary figure 1) and in the right striatum (20 × 20 × 20 mm3; supplementary figure 2). Spectra were acquired using Point RESolved Spectroscopy (PRESS, echo time = 35 ms; repetition time = 2000 ms; 128 averages, bandwidth/sample frequency ±2500 Hz, complex points = 4096), and analyzed in LCModel version 6.3-1L using a standard LCModel basis set. Representative spectra are provided in supplementary figure 3. Metabolite estimates were water-referenced. Gannet software (version 2.0, http://www.gabamrs.com) co-registered the 1H-MRS voxel to the corresponding T1-weighted image to determine the voxel tissue composition. Metabolite values were corrected for voxel tissue content using the formula:

\[
M_{corr} = M \times \left( \frac{WM + 1.21 \times GM + 1.55 \times CSF}{WM + GM} \right)
\]

where M is the uncorrected metabolite concentration, and WM, GM, and CSF indicate the percentages of tissue type in the voxel. Further details are provided in the supplementary information. The primary outcome variable was Glutamate. For completeness, data for glutamate plus glutamine (Glx) are also presented.

Quality of 1H-MRS was determined by a review of LCModel estimates of spectral line width and signal-to-noise ratio. Spectra were excluded under any of the following criteria: (1) absence of corresponding unsuppressed water acquisition; (2) compared with the overall mean for the voxel across all sites and participants, spectral line width was 2 standard deviations above; or (3) spectral signal-to-noise ratio was 2 standard deviations below. Individual metabolite concentration estimates associated with Cramér Rao lower bounds (CRLB) > 20% were excluded. We relied on these quality control procedures to identify and exclude any datasets potentially corrupted by motion or other artifacts.

3.4-Dihydroxy-6-[18F]Fluoro-L-Phenylalanine Positron Emission Tomography

Striatal dopamine function was measured using 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-DOPA) PET. The study acquired 18F-DOPA PET scans in participants who had also participated in 1H-MRS, at 2 sites (KCL and the UoM). To reduce the formation of radiolabeled 18F-DOPA metabolites, participants received carbidopa (150 mg) and entacapone (400 mg) orally 1 hour before 18F-DOPA imaging.

Thirty seconds after the start of PET image acquisition, approximately 150 MBq of 18F-DOPA was administered by bolus intravenous injection. Emission data were acquired in list mode over the 95-minute period immediately post-injection.

Head movement was corrected for by frame-by-frame realignment using mutual information image registration. An 18F-DOPA template, together with a striatal atlas and cerebellum were nonlinearly normalized to each PET summation image in Statistical Parametric Mapping version 12 (http://www.fil.ion.ucl.ac.uk/spm) running in Matlab 2015b (Mathworks Inc.). This process allows automatic placement of volumes of interest (VOI) on individual PET images. The rate constant for the uptake of 18F-DOPA in the striatum (K1) was calculated using graphical analysis adapted for a reference tissue input function, using the cerebellum as the reference region. We investigated K1 across the whole
striatal VOI, and in associative, sensorimotor, and limbic functional subdivisions reflecting the topographical arrangement of corticostriatal projections. As previously, data are reported across both hemispheres and we did not predict laterality of effect. Supplementary figure 4 provides an example of 18F-DOPA PET K<sub>corr</sub> images.

Statistical Analysis

Due to site effects (see supplementary information), ¹H-MRS metabolite concentration estimates and 18F-DOPA K<sub>corr</sub> values were converted to Z-scores, calculated by subtracting the site mean from individual values, before dividing by the site standard deviation. Potential influences of age or sex on Glu<sub>corr</sub> or ¹⁸F-DOPA K<sub>corr</sub> min⁻¹ were determined by Pearson’s correlation coefficient and t-tests. For primary analyses, analysis of variance compared Glu<sub>corr</sub> and 18F-DOPA K<sub>corr</sub> min⁻¹ in the antipsychotic R and antipsychotic NR groups, using a threshold for statistical significance of \( P < .05 \) (uncorrected) in SPSS (version 23, IBM). Where the effects of age or sex were detected, these variables were added to the model. To evaluate the accuracy of ACC Glu<sub>corr</sub> and striatal 18F-DOPA K<sub>corr</sub> min⁻¹ values in distinguishing between antipsychotic R and NR groups, receiver-operating curves (ROC) were estimated, using Stata (SE, version 14). The secondary analysis investigated correlation relationships between Glu<sub>corr</sub> and 18F-DOPA K<sub>corr</sub> min⁻¹ and PANSS scores using Pearson’s correlation coefficient. Effects of Glu<sub>corr</sub> on ¹⁸F-DOPA K<sub>corr</sub> by the group were analyzed using analysis of variance.

Results

Participant Characteristics

Ninety-two participants (antipsychotic R, \( n = 48 \); antipsychotic NR, \( n = 44 \)) completed ¹H-MRS imaging (table 1) and 54 (R, \( n = 25 \); NR, \( n = 29 \)) completed 18F-DOPA PET imaging (table 2). The demographic and clinical characteristics of the ¹H-MRS and PET samples by the site are provided in supplementary tables 1 and 2. For participants who completed both ¹H-MRS and PET, the mean interval between scans was 24.74 ± 25.06 days (range 1–116 days).

Glutamate Metabolite Levels

ACC Glu<sub>corr</sub> and Glx<sub>corr</sub> were related to age (\( N = 86; \text{Glu}_{corr} \ r = −.21; \text{P} = .05; \text{Glx}_{corr} \ r = −.27; \text{P} = .01 \); supplementary figure 4), and sex (mean ± s.d. Glu<sub>corr</sub> male: 0.10 ± 0.94; female: −0.52 ± 1.04; \( T_{84} = 2.21; \text{P} = .03; \text{Glx}_{corr} \text{ male: } 0.11 ± 0.93; \text{female: } −0.56 ± 1.09; \text{ } T_{84} = 2.40; \text{P} = .01 \)). There were no significant effects of current tobacco or cannabis use or antipsychotic CPZE dose (\( P > .14 \)). The NR group had significantly higher ACC Glu<sub>corr</sub> levels compared with the R group after adjustment for age and sex (main effect of group: \( \text{Glu}_{corr} \ F_{1,49} = 4.99; \text{P} = .03; \text{Glu}^2 = 0.06; \text{table 3, figure 1} \)). A similar result at threshold levels of significance was detected for Glx<sub>corr</sub> (\( F_{1,81} = 3.92; \text{P} = .05; \text{Glu}^2 = 0.05; \text{table 3, figure 1} \)). Interactions between group and age or group and sex did not show any evidence of an effect. After excluding participants who were currently taking benzodiazepines (\( n = 10 \)) or antidepressants (\( n = 14 \)), the effects of group on Glu<sub>corr</sub> remained borderline significant (\( P = .04 \) and \( P = .07 \), respectively). The effect of group was not significant in unadjusted analysis (\( \text{Glu}_{corr} \ F_{1,84} = 2.37; \text{P} = .13; \text{Glx}_{corr} \ F_{1,84} = 1.77; \text{P} = .19 \); table 3). ROC analysis of non-adjusted ACC Glu<sub>corr</sub> levels in the R and NR groups returned an area under curve (AUC) of 0.59 (figure 2). Subsequent empirical cut-point estimation returned an optimal cut point of 0.98, which was associated with a Youden index of 0.22, sensitivity = 0.73, specificity = 0.49, and AUC of 0.61. There were no significant correlations between ACC Glu<sub>corr</sub> and PANSS scores or CPZE dose (\( N = 86; \text{r} = −.04 \) to .15).

There was no association between striatal Glu<sub>corr</sub> and Glx<sub>corr</sub> and age (\( N = 83; \text{Glu}_{corr} \text{ r} = −.13, \text{P} = .25; \text{Glx}_{corr} \text{ r} = −.09, \text{P} = .44 \), or sex (\( T_{81} = 0.30, \text{P} = .77; \text{Glx}_{corr} \text{ } T_{81} = 1.76; \text{P} = .08 \)). There were also no significant effects of current tobacco or cannabis use or antipsychotic CPZE dose (\( P > .07 \)). There was no between-group difference in striatal Glu<sub>corr</sub> (\( F_{1,81} = 0.96; \text{P} = .33; \text{figure 1} \)) or Glx<sub>corr</sub> (\( F_{1,81} = 1.39; \text{P} = .24; \text{table 3} \), or significant correlations between striatal Glu<sub>corr</sub> or Glx<sub>corr</sub> and PANSS scores or CPZE dose (\( N = 83; \text{r} = −.17 \) to .11). Site differences were present across ¹H-MRS data (supplementary tables 3 and 4; supplementary Results).

Striatal Dopamine Function

Striatal 18F-DOPA K<sub>corr</sub> values were not associated with age (\( N = 54; \text{r} = .07; \text{P} = .61 \), sex (\( T_{52} = 0.66; \text{P} = .51 \), tobacco (\( F_{2,52} = .17; \text{P} = .85 \)), cannabis use (\( F_{1,52} = 1.20; \text{P} = .28 \)), or antipsychotic CPZE dose (\( r = .06; \text{P} = .67 \)). K<sub>corr</sub> did not differ between the R and NR groups (\( F_{1,52} = 1.24; \text{P} = .27 \); table 3, figure 1). ROC analysis of whole striatal 18F-DOPA K<sub>corr</sub> in antipsychotic R and NR returned an AUC of 0.59, K<sub>corr</sub> were not associated with PANSS scores or CPZE dose (\( r = −.01 \) to .13).

Relationships Between Glutamate and Dopamine

There was no main effect of ACC Glu<sub>corr</sub> on striatal 18F-DOPA K<sub>corr</sub> (\( F_{1,50} = 1.03; \text{P} = .31 \)), but the interaction between ACC Glu<sub>corr</sub> and group was significant (\( F_{1,50} = 6.53; \text{P} = .01 \)). This was related to a positive relationship between ACC Glu<sub>corr</sub> and striatal 18F-DOPA K<sub>corr</sub> in NR (\( N = 29; r = .37; \text{P} = .05 \)) but not in R (\( N = 25; r = −.31; \text{P} = .13 \)). Striatal Glu<sub>corr</sub> was negatively associated with striatal 18F-DOPA K<sub>corr</sub> across the whole
Dopamine, Glutamate, and Antipsychotic Response

The main aim of this study was to test whether measures of dopamine synthesis capacity in the striatum and glutamate concentration in the ACC could differentiate patients with antipsychotic nonresponsive schizophrenia from antipsychotic-responsive schizophrenia. In line with our hypothesis, we found that ACC mean Glu$_{corr}$ was higher in the NR compared with the R group, which was significant when age and sex were included in the model. There were no between-group differences in striatal dopamine function nor in striatal Glu$_{corr}$. These results are partially consistent with previous evidence that the degree of antipsychotic response in schizophrenia may be related to ACC glutamate concentration but not with evidence linking response to striatal dopamine function. The AUC for both glutamate and dopamine measures indicated low discriminative accuracy. This indicates that these measures alone are unlikely to be sufficiently sensitive to identify chronic patients with antipsychotic nonresponsive from responsive illness in routine clinical practice.

The higher mean ACC Glu$_{corr}$ in NR is broadly consistent with cross-sectional and prospective studies associating higher levels of ACC glutamatergic

### Table 1. Clinical and Demographic Characteristics of the $^1$H-MRS Sample

|                          | Antipsychotic Responder | Antipsychotic Nonresponder | $P$  |
|--------------------------|-------------------------|----------------------------|------|
| Sample size              | 48                      | 44                         |      |
| Age (years)              | $29.9 \pm 9.8$          | $28.9 \pm 7.5$             | .64  |
| Sex male/female          | 41/7                    | 36/8                       | .64  |
| Ethnicity                |                         |                            | .96  |
| White                    | 27                      | 24                         |      |
| Black                    | 13                      | 14                         |      |
| Asian                    | 4                       | 3                          |      |
| Other                    | 4                       | 3                          |      |
| Subtype                  |                         |                            | .19  |
| Psychosis unspecified    | 15                      | 7                          |      |
| Schizophrenia            | 33                      | 35                         |      |
| Delusional disorder      | 0                       | 1                          |      |
| Schizoaffective disorder | 0                       | 1                          |      |
| Current antipsychotic    |                         |                            | .60  |
| Aripiprazole             | 11                      | 8                          |      |
| Olanzapine               | 15                      | 7                          |      |
| Risperidone              | 9                       | 5                          |      |
| Amisulpride              | 2                       | 4                          |      |
| Quetiapine               | 3                       | 9                          |      |
| Paliperidone             | 1                       | 4                          |      |
| Zuclopenthixol           | 2                       | 1                          |      |
| Flupentixol              | 1                       | 1                          |      |
| Haloperidol              | 1                       | 0                          |      |
| Combination              | 3                       | 5                          |      |
| CPZE mg/day              | $426.5 \pm 241.5$       | $515.9 \pm 379.6$          | .18  |
| Other CNS medications    |                         |                            |      |
| None                     | 40                      | 34                         |      |
| Antidepressants          | 5                       | 9                          | .15  |
| Benzodiazepines          | 4                       | 6                          | .73  |
| Age onset                | $24.6 \pm 6.8$          | $23.8 \pm 6.4$             | .56  |
| Duration of illness      | $5.1 \pm 7.9$           | $5.1 \pm 5.1$              | .99  |
| Tobacco daily/less daily | 21/423                  | 17/324                     | .59  |
| Cannabis ever Y/N        | 34/14                   | 37/7                       | .25  |
| Cannabis current Y/N     | 7/41                    | 5/39                       | .76  |
| Prior substance use disorder Y/N | 1/47               | 0/44                       |      |
| PANSS positive           | $12.0 \pm 3.1$          | $22.5 \pm 3.5$             |      |
| PANSS negative           | $13.5 \pm 3.3$          | $20.9 \pm 4.8$             |      |
| PANSS general            | $27.2 \pm 4.3$          | $43.3 \pm 5.3$             |      |
| PANSS total              | $52.7 \pm 6.7$          | $86.7 \pm 8.8$             |      |

**Note:** Data are expressed as mean ± standard deviation unless otherwise specified. $^1$H-MRS, $^1$H-magnetic resonance spectroscopy; CNS, central nervous system; CPZE, chlorpromazine equivalent dose; PANSS, Positive and Negative Syndrome Scale. Current cannabis use was defined as use within the last 7 days. $P$ values relate to independent samples t-tests, Chi square, or Fisher’s exact test as appropriate. There were no significant group differences in clinical or demographic characteristics other than in PANSS scores.

sample ($F_{1.50} = 4.97; P = .03$), and there was no group by striatal Glu$_{corr}$ interaction ($F_{1.50} = 2.02; P = .16$).

### Discussion

The main aim of this study was to test whether measures of dopamine synthesis capacity in the striatum and glutamate concentration in the ACC could differentiate patients with antipsychotic-nonresponsive schizophrenia. In line with our hypothesis, we found that ACC mean Glu$_{corr}$ was higher in the NR compared with the R group, which was significant when age and sex were included in the model. There were no between-group differences in striatal dopamine function nor in striatal Glu$_{corr}$. These results are partially consistent with previous evidence that the degree of antipsychotic response in schizophrenia may be related to ACC glutamate concentration but not with evidence linking response to striatal dopamine function. The AUC for both glutamate and dopamine measures indicated low discriminative accuracy. This indicates that these measures alone are unlikely to be sufficiently sensitive to identify chronic patients with antipsychotic nonresponsive from responsive illness in routine clinical practice.

The higher mean ACC Glu$_{corr}$ in NR is broadly consistent with cross-sectional and prospective studies associating higher levels of ACC glutamatergic...
Table 2. Clinical and Demographic Characteristics of the $^{18}$F-DOPA PET Sample

|                                      | Antipsychotic Responder | Antipsychotic Nonresponder | $P$  |
|--------------------------------------|-------------------------|---------------------------|------|
| Sample size                          | 25                      | 29                        |      |
| Age (years)                          | 29.8 ± 9.6              | 30.0 ± 8.3                | .86  |
| Sex male/female                      | 21/4                    | 24/5                      | 1.00 |
| Ethnicity                            |                         |                           | .77  |
| White                                | 10                      | 11                        |      |
| Black                                | 9                       | 13                        |      |
| Asian                                | 3                       | 3                         |      |
| Other                                 | 3                       | 2                         |      |
| Subtype                              |                         |                           | .23  |
| Psychosis unspecified                | 8                       | 6                         |      |
| Schizophrenia                        | 17                      | 21                        |      |
| Delusional disorder                  | 0                       | 1                         |      |
| Schizoaffective disorder             | 0                       | 1                         |      |
| Current antipsychotic                | 7                       | 6                         | .53  |
| Aripiprazole                         | 7                       | 4                         |      |
| Olanzapine Risperidone               | 5                       | 2                         |      |
| Amisulpride                          | 2                       | 3                         |      |
| Quetiapine                           | 1                       | 4                         |      |
| Paliperidone                         | 0                       | 4                         |      |
| Clopixol                             | 1                       | 1                         |      |
| Flupenthixol                         | 1                       | 1                         |      |
| Haloperidol                          | 1                       | 0                         |      |
| Combination                          | 0                       | 4                         |      |
| CPZE (mg/day)                        | 404.8 ± 224.6           | 557.8 ± 420.9             | .11  |
| Other CNS medications                |                         |                           |      |
| None                                 | 21                      | 23                        |      |
| Antidepressants                      | 4                       | 5                         | 1.00 |
| Benzodiazepines                      | 1                       | 3                         | .62  |
| Age onset                            | 23.4 ± 5.5              | 24.1 ± 6.9                | .72  |
| Duration of illness                  | 5.9 ± 9.1               | 5.9 ± 5.7                 | .98  |
| Tobacco daily/less than daily/not at all | 10/2/13               | 10/1/18                   | .57  |
| Cannabis ever Y/N                    | 17/8                    | 23/6                      | .37  |
| Cannabis current Y/N                 | 3/22                    | 3/26                      | 1.00 |
| PANSS positive                       | 12.8 ± 3.2              | 22.0 ± 3.7                |      |
| PANSS negative                       | 13.3 ± 3.1              | 22.3 ± 4.4                |      |
| PANSS general                        | 27.0 ± 2.9              | 42.6 ± 5.1                |      |
| PANSS total                          | 53.1 ± 5.5              | 86.9 ± 9.5                |      |

$^{18}$F-DOPA dose MBq

$^{18}$F-DOPA PET, 3,4-dihydroxy-6-[18F]fluorophenylalanine positron emission tomography; CNS, central nervous system; CPZE, chlorpromazine equivalent dose; PANSS, Positive and Negative Syndrome Scale. Current cannabis use was defined as use within the last 7 days. $P$ values relate to independent samples $t$-tests, Chi square, or Fisher’s exact test as appropriate. There were no significant group differences in clinical or demographic characteristics other than in PANSS scores.

Note: Data are expressed as mean ± standard deviation unless otherwise specified.

metabolites with a poor antipsychotic response. However, these studies differ in the glutamate measurement (glutamate or Glx) or Glu ratios (to creatine), sometimes corrected for voxel tissue composition. In addition, 2 studies did not detect differences in ACC glutamate metabolites between a TRS and antipsychotic R group,28,33 and 1 found ACC Glx, but not glutamate, was elevated in patients with ultra-resistant schizophrenia (URS) compared with healthy volunteers, but not in TRS or URS compared with antipsychotic responders.27 Together with the current findings, the overall literature not only may indicate an association between elevated ACC glutamatergic metabolites and antipsychotic nonresponse but also suggests that effect sizes may be small and influenced by methodological factors and sample characteristics. In terms of biological mechanism, one explanation is that patients who are less likely to respond to treatment exhibit greater elevations in frontal glutamate metabolites, potentially linked to a greater degree of N-methyl-D-aspartate (NMDA) receptor or gamma-aminobutyric acid (GABA)ergic dysfunction resulting from genetic or developmental mechanisms. In addition, antipsychotic medication could have less impact on frontal glutamatergic dysfunction in those who respond poorly to treatment. In the striatum, the lack of group difference in Glu$_{corr}$ is consistent with 2 recent cross-sectional studies examining TRS to first-line antipsychotic responders or healthy volunteers.27,28 This could indicate that elevations in striatal
glutamate at illness onset\textsuperscript{31,32} are reduced during antipsychotic treatment\textsuperscript{34} irrespective of the response category. Alternatively, as we also observed no group difference in striatal 18F-DOPA $K_{\text{corr}}$, these findings may indicate that the participants selected for our samples did not markedly differ in the overall striatal pathophysiology.

In the 54 patients with dopamine measures evaluated across 2 sites, there was no group difference in striatal 18F-DOPA $K_{\text{corr}}$, indicating similar levels of presynaptic dopamine synthesis and storage capacity. This finding differs from previous smaller studies that have associated increased striatal dopamine function with a good antipsychotic response.\textsuperscript{30,24} Using the same 18F-DOPA PET method, we reported lower striatal $K_{\text{corr}}$ in 12 patients with TRS compared with 12 antipsychotic responders.\textsuperscript{20} In another study comparing a TRS group currently taking clozapine with antipsychotic-responsive patients, the resistant group again had lower $K_{\text{corr}}$ than the responders.\textsuperscript{21}

In first-episode psychosis, striatal 18F-DOPA $K_{\text{corr}}$ was positively related to subsequent antipsychotic response.\textsuperscript{24} Lower

### Table 3. Glutamate and Dopamine Measures in the Antipsychotic Responder and Antipsychotic Nonresponder Groups

|                      | Antipsychotic Responder | Antipsychotic Nonresponder | ES, or GLM, Group | GLM: Group, Age, and Sex |
|----------------------|-------------------------|---------------------------|--------------------|--------------------------|
| **1H-MRS glutamate (Glu$_{\text{i}}$)** |                          |                          |                    |                          |
| Anterior cingulate cortex |                          |                          |                    |                          |
| KCL                  | 19.39 ± 3.56 (16)        | 20.29 ± 2.63 (18)        | $d = 0.29$         |                          |
| UoM                  | 13.74 ± 1.75 (17)        | 14.28 ± 1.59 (15)        | $d = 0.74$         |                          |
| UoE                  | 12.57 ± 1.18 (7)         | 13.33 ± 0.90 (5)         | $d = 0.72$         |                          |
| CU                   | 11.65 ± 1.68 (5)         | 11.57 ± 2.22 (3)         | $d = 0.04$         |                          |
| Overall              | −0.15 ± 1.05 (45)        | 0.17 ± 0.88 (41)         | $F_{1,54} = 2.37; P = .13; \eta^2 = 0.03$ | $F_{1,51} = 4.99; P = .03; \eta^2 = 0.06$ |
| **1H-MRS Glx (Glx$_{\text{i}}$)** |                          |                          |                    |                          |
| Anterior cingulate cortex |                          |                          |                    |                          |
| KCL                  | 25.86 ± 5.28 (16)        | 26.85 ± 4.28 (18)        | $d = 0.21$         |                          |
| UoM                  | 19.67 ± 2.56 (17)        | 20.17 ± 1.87 (15)        | $d = 0.22$         |                          |
| UoE                  | 18.59 ± 1.61 (7)         | 19.62 ± 1.87 (5)         | $d = 0.59$         |                          |
| CU                   | 14.82 ± 2.15 (5)         | 15.36 ± 2.14 (3)         | $d = 0.34$         |                          |
| Overall              | −0.13 ± 1.06 (45)        | 0.15 ± 0.88 (41)         | $F_{1,54} = 1.77; P = .19; \eta^2 = 0.02$ | $F_{1,51} = 3.92; P = .05; \eta^2 = 0.05$ |
| **18F-DOPA PET K$_{\text{corr}}$** |                          |                          |                    |                          |
| Whole striatum       |                          |                          |                    |                          |
| KCL                  | 0.0125 ± 0.0095 (11)     | 0.0128 ± 0.0010 (16)     | $d = 0.04$         |                          |
| UoM                  | 0.0139 ± 0.0013 (14)     | 0.0143 ± 0.0010 (13)     | $d = 0.34$         |                          |
| Overall              | −0.18 ± 1.05 (25)        | 0.12 ± 0.93 (29)         | $F_{1,52} = 1.24; P = .27; \eta^2 = 0.02$ |                          |
| Sensorimotor striatum |                          |                          |                    |                          |
| KCL                  | 0.0126 ± 0.0011 (11)     | 0.0149 ± 0.0010 (16)     | $d = 2.19$         |                          |
| UoM                  | 0.0149 ± 0.0016 (14)     | 0.0156 ± 0.0010 (13)     | $d = 0.52$         |                          |
| Overall              | −0.25 ± 0.96 (25)        | 0.16 ± 0.95 (29)         | $F_{1,52} = 2.54; P = .12; \eta^2 = 0.05$ |                          |
| Associative striatum |                          |                          |                    |                          |
| KCL                  | 0.0126 ± 0.0010 (11)     | 0.0128 ± 0.0010 (16)     | $d = 0.2$          |                          |
| UoM                  | 0.0136 ± 0.0014 (14)     | 0.0138 ± 0.0010 (13)     | $d = 0.16$         |                          |
| Overall              | −0.13 ± 1.07 (25)        | 0.09 ± 0.95 (29)         | $F_{1,52} = 0.62; P = .44; \eta^2 = 0.01$ |                          |
| Limbic striatum      |                          |                          |                    |                          |
| KCL                  | 0.0122 ± 0.0010 (11)     | 0.0128 ± 0.0010 (16)     | $d = 0.6$          |                          |
| UoM                  | 0.0136 ± 0.0012 (14)     | 0.0139 ± 0.0010 (13)     | $d = 0.3$          |                          |
| Overall              | −0.14 ± 1.05 (25)        | 0.12 ± 0.99 (29)         | $F_{1,52} = 0.86; P = .36; \eta^2 = 0.02$ |                          |

Note: Data are presented by site and as overall Z-score. Data are expressed as mean ± standard deviation (number of observations). ES, effect size; GLM, general linear model; $^1$H-MRS, $^1$H-magnetic resonance spectroscopy; $^{18}$F-DOPA PET, 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine positron emission tomography; KCL, King’s College London; UoM, University of Manchester; UoE, University of Edinburgh; CU, Cardiff University.
Glutamate and dopamine measures in the antipsychotic responder and antipsychotic nonresponder groups. Glutamate is expressed as the corrected $^1$H-MRS glutamate concentration (Glu$_{corr}$) in the anterior cingulate cortex (ACC) and right striatum. Dopamine synthesis was measured as $^{18}$F-DOPA $K_{cer}$ across the whole striatum. Values are presented as $Z$-scores. Data are shown in antipsychotic responder (R) and antipsychotic nonresponder (NR) groups.

Within cortico-striatal networks, counterbalancing pathways and feedback loops regulate neurotransmitter balance. For example, glutamate release can both increase and decrease dopamine levels, and dopamine receptor activation modulates glutamate release, and dopamine neurons may co-release glutamate. In NR only, ACC Glu$_{corr}$ was positively correlated to striatal $^{18}$F-DOPA $K_{cer}$. In contrast, striatal Glu$_{corr}$ and striatal $K_{cer}$ were negatively correlated across the whole sample. We previously found that ACC glutamate and striatal $K_{cer}$ were negatively correlated in patients with early psychosis and no significant relationship between these variables in healthy controls. Correlations between striatal glutamate and striatal $K_{cer}$ have not previously been investigated in patients but are positively correlated in healthy volunteers. Together these findings could suggest that glutamate-dopamine relationships may change with illness onset, progression, or antipsychotic response. One potential mechanism may involve alterations in the balance between the opposing influences of direct and indirect glutamatergic projections from the cortex to mesostriatal dopamine neurons. This interpretation could be further examined in animal models and in longitudinal patient studies over the course of antipsychotic treatment.

Relative to previous research, a strength of the current study is the large sample size, which reduces the risk of false-positive findings. There are also design differences compared with previous studies that may contribute to the lack of group difference in dopamine measures and the marginal group difference in ACC glutamate measures. The criteria used to define the antipsychotic NR and R groups may have led to less clinical separation of these groups than in our previous $^{18}$F-DOPA PET and $^1$H-MRS studies. In the current study, the R group criteria allowed a higher level of symptom severity, while the NR group was less symptomatic and met fewer of the criteria for establishing treatment resistance. In addition, although the 2 groups were relatively well-matched for medication, we did not confirm adherence by measuring blood plasma antipsychotic levels. It is thus possible that the NR group may have included some participants whose symptoms were high because of partial nonadherence, rather than because they were “true” nonresponders.

Further strengths of our study include the establishment of collaborative multicenter $^1$H-MRS and PET imaging in the UK, which allowed us to achieve a large sample size for both $^1$H-MRS and $^{18}$F-DOPA PET imaging. With a view toward developing predictive biomarkers for stratified clinical trials, we formally assessed the accuracy of these measures for classifying antipsychotic response and nonresponse. In our previous multicenter $^1$H-MRS study in first-episode psychosis, our a priori outcome variable was glutamate in ratio to creatine. In the current multicenter study, we were able to correct glutamate estimates for voxel tissue composition (Glu$_{corr}$, our primary outcome variable) by applying the same software (Gannet) to extract voxel tissue fractions.
in data acquired across different MRI systems. This has the advantage that potential influences of voxel creatine content (otherwise often used as an internal standard) are avoided (see supplementary Discussion).

Our study also has several limitations. It is not possible to establish the proportion of the NR group that would meet Treatment Response and Resistance In Psychosis (TRRIP) consensus requirements for “TRS” as we did not include a prospective trial of antipsychotic medication or collect objective evidence of adherence. As we only collected clinical data at a single time-point, we did not establish the stability of R/NR status. These factors could have led to a less clinical separation between the R and NR groups and reduced our ability to observe differences in glutamate or dopamine measures. While the R and NR groups did not differ in duration of illness or current antipsychotic dose, the inclusion of patients who had been taking antipsychotic medication for some time may have influenced both 18F-DOPA $K_{1e}$ and 1H-MRS glutamate$^{21}$ values. The absence of a healthy control group means that we are unable to interpret 1H-MRS glutamate and 18F-DOPA $K_{1e}$ values in comparison to what may be expected in psychiatrically healthy individuals. Neither the 1H-MRS glutamate nor 18F-DOPA PET dopamine imaging measures specifically index neurotransmission. 1H-MRS estimates the total amount of intracellular glutamate in the voxel, including neurons as well as other cell types. 18F-DOPA is used to index presynaptic dopamine synthesis and storage capacity rather than dopamine release. Previous studies of glutamate in relation to antipsychotic response/nonresponse at a field strength of 3 tesla have detected differences in glutamate or Glx. Although glutamate values obtained with short TE PRESS at 3 tesla are routinely reported and published, glutamate can be difficult to reliably quantify without specialized sequences. Despite the fitting methods, the glutamate signal is likely to include some contamination from glutamine and macromolecules and this may vary across the site. As for other imaging modalities, there was between-scanner variation in both 1H-MRS and PET data, which will have reduced the sensitivity of our study. Although we did not detect significant site by group interactions, we cannot exclude the possibility that scanner variation impacted our results. Between-scanner variation is discussed further in the supplementary Discussion.

The results highlight the importance of considering age and sex effects in future studies of glutamate in schizophrenia. A lower level of ACC Glu$_{con}$ in older patients with schizophrenia is consistent with other reports. There is some evidence that age-related decline in ACC glutamate is greater in schizophrenia than in healthy aging, although other studies have reported similar rates of ACC glutamate decrease in patients and healthy volunteers. Our finding of higher ACC Glu$_{con}$ levels in male compared with female participants is less clear due to the relatively small number of female participants.

In conclusion, our findings support previous research linking increases in ACC glutamate to a poor antipsychotic response. However, the poor group discrimination suggests that glutamate 1H-MRS or 18F-DOPA measures alone cannot distinguish between antipsychotic responsive and nonresponsive groups after a mean of 5–6 years of illness. Multicenter, cross-platform 1H-MRS and PET studies are rare, and in future studies, sensitivity may be improved through greater harmonization. It is also possible that glutamatergic and dopaminergic markers may have more predictive power earlier in the course of the disorder before the potentially confounding effects of treatment and illness duration have taken effect. They may also have increased predictive power in combination with other factors that may associate with antipsychotic response, such as clinical and demographic measures, brain network connectivity, genetic factors, and blood measures. We plan to address these issues in future studies.

Supplementary Material

Supplementary material is available at Schizophrenia Bulletin.

Funding

This research was supported by the Medical Research Council (MRC) UK, Stratified Medicines Initiative, reference MR/L011794/1 ‘STRATA’. Research at the London site was supported by the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Center for Mental Health award to South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Acknowledgments

G.J.B. receives honoraria for teaching from General Electric Healthcare. In the past 3 years, S.M.L. has received research support from Janssen and Lundbeck, and personal fees from Janssen, Otsuka, and Sunovion. The remaining authors report no conflicts of interest.

Data Availability

At the time of submission, the data governance frameworks are being put in place to make a fully anonymized version of the data available to the wider research community via TranSMART data sharing platform: https://transmartfoundation.org/, which will be hosted at the MRC eMedLab: https://www.emedlab.ac.uk/. To apply
for access to the data, please contact J.H.M. at james.maccabe@kcl.ac.uk.

References

1. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizoaffective disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097.

2. Boter H, Peusken J, Libiger J, et al.; EUFEST study group. Effectiveness of antipsychotics in first-episode schizophrenia and schizoaffective disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115(2-3):97–103.

3. Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.

4. Lehman AF, Lieberman JA, Dixon LB, et al.; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56.

5. Mullins PG, McGonigle DJ, O’Gorman RL, et al.; Cardiff Symposium on MRS of GABA. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage. 2014;86:43–52.

6. Meltzer HY. Treatment-resistant schizophrenia—the role of clozapine. Cur Med Res Opin. 1997;14(1):1–20.

7. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481–485.

8. Yoshimura B, Yada Y, So R, Takaki M, Yamada N. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res. 2017;250:65–70.

9. Gillespie AL, Samanaita R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry. 2017;17(1):12.

10. Stone JM, Raffin M, Morrison P, McGuire PK. Review: The biological basis of antipsychotic response in schizophrenia. J Psychopharmacol. 2010;24(7):953–964.

11. Lally J, Ajnakina O, Di Fori M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46(15):3231–3240.

12. Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981–1989.

13. Wimberley T, Stovring H, Sorensen HJ, Horsdal HT, MacCabe JH, Gasse C. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry. 2016;3(4):358–366.

14. Mouchlianitis E, Bloomfield MA, Law V, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2016;42(3):744–752.

15. Howes OD, McCutcheon R, Owen MJ, Murray RM. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. 2017;81(1):9–20.

16. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081–1090.

17. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry. 1989;146(7):905–908.

18. Piolowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med. 1993;23(3):791–797.

19. Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry. 2014;205(1):1–3.

20. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169(11):1203–1210.

21. Kim E, Howes OD, Veronese M, et al. Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [18F]F-DOPA PET study. Neuropsychopharmacology. 2017;42(4):941–950.

22. Abi-Dargham A, Rodenhus R, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A. 2000;97(14):8104–8109.

23. Wulff S, Pinborg LH, Syrjanen C, et al. Striatal D(2/3) binding potential values in drug-naive first-episode schizophrenia patients correlate with treatment outcome. Schizophr Bull. 2015;41(5):1143–1152.

24. Jauhar S, Veronese M, Nour MM, et al. Determinants of treatment response in first-episode psychosis: an [18F]-DOPA PET study. Mol Psychiatry. 2019;24(10):1502–1512.

25. Moghaddam B, Javitt D. From revolution to revolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4–15.

26. Egerton A, Brugger S, Raffin M, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012;37(11):2515–2521.

27. Iwata Y, Nakajima S, Plitman E, et al. Glutamatergic neurometabolite levels in patients with ultra-treatment-resistant schizophrenia: a cross-sectional 3T proton magnetic resonance spectroscopy study. Biol Psychiatry. 2019;85(7):596–605.

28. Tarumi R, Tsugawa S, Noda Y, et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Prog Neurobiol. 2020;185(1):1033–1069.

29. Egerton A, Broberg BV, Van Haren N, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre [1H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23(11):2145–2155.

30. Szulc A, Konarzewska B, Galinska-Skow B, et al. Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia. Neurosci Lett. 2013;547:37–41.

31. de la Fuente-Sandoval C, Leon-Ortiz P, Faviola R, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology. 2011;36(9):1781–1791.

32. Plitman E, de la Fuente-Sandoval C, Reyes-Madrigal F, et al. Elevated myo-inositol, choline, and glutamate levels in the associative striatum of antipsychotic-naive patients.
with first-episode psychosis: a proton magnetic resonance spectroscopy study with implications for glial dysfunction. Schizophr Bull. 2016;42(2):415–424.

33. Goldstein ME, Anderson VM, Pillai A, Kydd RR, Russell BR. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18(6):1–9.

34. de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA psychiatry. 2013;70(10):1057–1066.

35. de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, et al. Prefrontal and striatal gamma-aminobutyric acid levels and the effect of antipsychotic treatment in first-episode psychosis patients. Biol Psychiatry. 2018;83(6):475–483.

36. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2013;75(5):e11–3.

37. Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80(2):18com12123.

38. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22–33; quiz 34–57.

39. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192–208.

40. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.

41. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta psychiatr scand. 2003;(416):16–23.

42. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231–238.

43. Kim R, Hayward P, Applewhaite G, Everett B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312(7027):345–349.

44. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672–679.

45. Kreis R, Ernst T, Ross BD. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med. 1993;30(4):424–437.

46. Gasparovic C, Song T, Devier D, et al. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med. 2006;55(6):1219–1226.

47. Cuming P, Léger GC, Kuwabara H, Gjedde A. Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Dopa) in humans. J Cereb Blood Flow Metab. 1993;13(4):68–75.

48. Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson’s disease. Neurology. 1994;44(7):1292–1297.

49. Studholme C, Hill DL, Hawkes DJ. Automated 3-D registration of MR and CT images of the head. Med Image Anal. 1996;1(2):163–175.

50. Turkheimer FE, Brett M, Visvikis D, Cunningham VJ. Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab. 1999;19(11):1189–1208.

51. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry. 2004;61(2):134–142.

52. Martinez D, Sliifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003;23(3):283–300.

53. Bloomfield MA, Pepper F, Egerton A, et al. Dopamine function in cigarette smokers: an [18F]-DOPA PET study. Neuropsychopharmacology. 2014;39(10):2397–2404.

54. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985;5(4):584–590.

55. Turkheimer FE, Aston JA, Asselin MC, Hinz R. Multiresolution Bayesian regression in PET dynamic studies using wavelets. Neuroimage. 2006;32(1):111–121.

56. Haber SN. The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat. 2003;26(4):317–330.

57. Hädel S, Wirth C, Rapp M, Gallinat J, Schubert F. Effects of age and sex on the concentrations of glutamate and glutamine in the human brain. J Magn Reson Imaging. 2013;38(6):1480–1487.

58. Wijtenburg SA, Wright SN, Korenic SA, et al. Altered glutamate and regional cerebral blood flow levels in schizophrenia: a 1H-MRS and pCASL study. Neuropsychopharmacology. 2017;42(2):562–571.

59. Marsman A, van den Heuvel MP, Klompen HU, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. Schizophr Bull. 2013;39(1):120–129.

60. Sailasuta N, Ernst T, Chang L. Regional variations and the effects of age and gender on glutamate concentrations in the human brain. Magn Reson Imaging. 2008;26(5):667–675.

61. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia—therapeutic implications. Biol Psychiatry. 1999;46(10):1388–1395.

62. Mora F, Segovia G, Del Arco A. Glutamate-dopamine-GABA interactions in the aging basal ganglia. Brain Res Rev. 2008;58(2):340–353.

63. Wang W, Dever D, Lowe J, et al. Regulation of prefrontal excitatory neurotransmission by dopamine in the nucleus accumbens core. J Physiol. 2012;590(16):3743–3769.

64. Sulzer D, Joyce MP, Lin L, et al. Dopamine neurons make glutamatergic synapses in vitro. J Neurosci. 1998;18(12):4588–4602.

65. Jauhar S, McCutcheon R, Borgan F, et al. The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. Lancet Psychiatry. 2018;5(10):816–823.
67. Gleich T, Deserno L, Lorenz RC, et al. Prefrontal and striatal glutamate differently relate to striatal dopamine: potential regulatory mechanisms of striatal presynaptic dopamine function? *J Neurosci.* 2015;35(26):9615–9621.

68. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. *Am J Psychiatry.* 2017;174(3):216–229.

69. McCutcheon R, Beck K, D’Ambrosio E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. *Acta Psychiatr Scand.* 2018;137(1):39–46.

70. Vernaleken I, Kumakura Y, Cumming P, et al. Modulation of \(^{[18]}\)Ffluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. *Neuroimage.* 2006;30(4):1332–1339.

71. Egerton A, Bhachu A, Merritt K, McQueen G, Szulc A, McGuire P. Effects of antipsychotic administration on brain glutamate in schizophrenia: a systematic review of longitudinal \(^1\)H-MRS studies. *Front Psychiatry.* 2017;8:66.

72. Brandt AS, Unschuld PG, Pradhan S, et al. Age-related changes in anterior cingulate cortex glutamate in schizophrenia: a \(^{1}\)H-MRS study at 7 tesla. *Schizophr Res.* 2016;172(1-3):101–105.

73. Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. *JAMA Psychiatry.* 2016;73(7):665–674.

74. Sarpal DK, Argyelan M, Robinson DG, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. *Am J Psychiatry.* 2016;173(1):69–77.

75. Ruderfer DM, Charney AW, Readhead B, et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. *Lancet Psychiatry.* 2016;3(4):350–357.

76. Wimberley T, Gasse C, Meier SM, Agerbo E, MacCabe JH, Horsdal HT. Polygenic risk score for schizophrenia and treatment-resistant schizophrenia. *Schizophr Bull.* 2017;43(5):1064–1069.

77. Martinuzzi E, Barbosa S, Daoudlarian D, et al.; OPTiMiSE Study Group. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. *Transl Psychiatry.* 2019;9(1):20.